Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to Section H of the Pharmaceutical Schedule. For community funding, see the Special Authority Criteria.

PRESCRIBER	PATIENT:
Name:	Name:
Ward:	NHI:
Baricitinib	
INITIATION – moderate to severe COVID-19* Re-assessment required after 14 days Prerequisites (tick boxes where appropriate) O Patient has confirmed (or probable) COVID-19* and O Oxygen saturation of < 92% on room air, or requiring supplemental oxygen and O Patient is receiving adjunct systemic corticosteroids, or systemic corticosteroids are contraindicated and O Baricitinib is to be administered at doses no greater than 4 mg daily for up to 14 days and O Baricitinib is not to be administered in combination with tocilizumab	
Note: Indications marked with * are unapproved indications.	